"West Kazakhstan Marat Ospanov Medical Unversity" Repository
Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study
JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Topolyanskaya, Svetlana V | |
| dc.contributor.author | Rachina, S.A. | |
| dc.contributor.author | Lytkina, Karine A. | |
| dc.contributor.author | Melkonyan, Georgiy G. | |
| dc.contributor.author | Savochkina, Yulia A | |
| dc.date.accessioned | 2025-01-13T08:11:34Z | |
| dc.date.available | 2025-01-13T08:11:34Z | |
| dc.date.issued | 2024-12-20 | |
| dc.identifier.other | DOI: 10.18502/wkmj.v66i4.17780 | |
| dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/429 | |
| dc.description | A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a significant reduction in body temperature, decrease in CRP, and an increase in the levels of blood cells. Revealed clinical improvement was seen in 69.7% of cases, 8.5% of patients showed deterioration in their condition and were transferred to the ICU, 13.6% died. Olokizumab was well tolerated except for slight elevation in live enzymes, such as aspartate transaminase and alanine transaminase. | ru |
| dc.description.abstract | A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a significant reduction in body temperature, decrease in CRP, and an increase in the levels of blood cells. Revealed clinical improvement was seen in 69.7% of cases, 8.5% of patients showed deterioration in their condition and were transferred to the ICU, 13.6% died. Olokizumab was well tolerated except for slight elevation in live enzymes, such as aspartate transaminase and alanine transaminase. | ru |
| dc.language.iso | en | ru |
| dc.publisher | West Kazakhstan Medical Journal | ru |
| dc.subject | COVID-19 | ru |
| dc.subject | C-reactive protein | ru |
| dc.subject | interleukin-6 | ru |
| dc.subject | olokizumab How | ru |
| dc.title | Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study | ru |
| dc.type | Article | ru |
